Healthcare giant Covidien has entered into an agreement with VIDA Diagnostics, a pioneer in quantitative pulmonary imaging analysis software. Under the agreement, Covidien will distribute VIDA’s Apollo® pulmonary imaging software services.
Lung cancer is a public health issue that affects more than 370,000 Americans and represents a $14 billion expense each year, according to the American Lung Association. Chronic Obstructive Pulmonary Disorder (COPD) is the third leading cause of death in the United States and adds $18 billion in annual healthcare spend.
Covidien’s i-Logic system uses advanced Electromagnetic Navigation Bronchoscopy® technology to extend beyond the capabilities of the bronchoscope to distant regions of the lungs not accessible through traditional bronchoscopy. The system enables physicians to locate previously inaccessible small lung lesions for diagnostic testing and enhancing treatment options.
Vida Diagnostics is a leading developer of quantitative imaging analysis software for the diagnosis and treatment planning of major pulmonary disease. It’s Apollo platform provides more precise analyses of imaging data for more objective insights on patient diagnoses and treatment options.
This agreement enables Covidien to offer a unique combination of market-leading technologies from Vida and its own i-Logic™ lung navigation system.
“The integration of quantitative pulmonary image analysis with innovative devices and therapies is an emerging requirement to obtain effective outcomes in patients with lung disease,” said Scott Ferguson, M.D., Associate Professor and Director of Interventional Pulmonology in the Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health; who has worked as a consultant to Covidien. “Together, VIDA and Covidien, leaders in their specialized fields, provide a more unified, comprehensive approach to managing patients with lung disease.”
“We are committed to improving patient outcomes. The combination of our technologies results in a powerful, minimally invasive, more informative imaging solution for areas of the lung not accessible by traditional bronchoscopy and for patients who cannot tolerate more invasive procedures,” said Michael Minette, Vice President, Interventional Lung Solutions, Covidien. “This collaboration brings together two companies dedicated to the early detection, evaluation and treatment of pulmonary disease.”
“Our partnership with Covidien is an opportunity to transform the management of patients with lung disease to an objective, evidence-based approach leading to more precise diagnoses and targeted therapies,” said Susan A. Wood, Ph.D., President and CEO of VIDA Diagnostics. “We are thrilled to be collaborating with the leaders in minimally invasive techniques to bring new diagnostic and therapeutic planning opportunities for patients with lung disease.”